The second generation targeted drug developed by Chugai Pharmaceutical for ALK positive non-small cell lung cancer patients has been confirmed by the National Cancer Information Network (NCCN) in empirical medicine, and it has also won the Bronze Medal for Prescription Drugs in the 2019 National Biotechnology Medical Quality Award. Academician of the Academia Sinica Mr. Peng highly praised the milestone.

The majority of ALK-positive non-small cell lung cancer patients are female, young, and have no history of smoking. In addition to treating primary lung cancer, 60% of them face brain metastasis. The second generation targeted drug of Chguai is an oral ALK inhibitor. It selectively inhibits ALK activation to inhibit cancer cell proliferation and induce cancer cell death. The most important thing is to penetrate the blood-brain barrier. Regardless of whether the patient has previously merged, the drug can delay brain metastasis speed, effectively control side effects, and improve the quality of life of patients. This targeted drug was approved as a second-line drug for health insurance in November 2017, and was included in a first-line drug for health insurance on December 1, 2019.

Unlikely big pharma companies, Chugai Pharmaceutical obtains a small business size in Taiwan, but it still set up Clinical Development department to constantly extend the drug research and development scope from headquarter, actively participate in various global programs, making Taiwan become an essential partner when conducting global clinical trials. Chugai Pharma Taiwan commits to the development of innovative products to accelerate the time to market of new drugs in Taiwan.

Susan Chou, HR Director of Chugai Pharma Taiwan, mentioned that the company pays high attention on employee satisfaction. For example, we cooperate with consulting firms to review and amend HR policies every few years. Since this June, employees can choose to work from home for two days a month. For employees who will be abroad, they can work from home the day before and pack their luggage while working, which even increases work efficiency. In June this year, Chugai Pharma Taiwan won the Best Employer Award in 2019.

Besides, giving back to society is a part of the active investment of Chugai Pharma Taiwan. It not only adopts the eight sidewalk trees in front of the company to make the night brighter, also donates supplement to nursing home at Yilan, Keelung, Xiaoliuqiu, Penghu, Kinmen, etc. In 2020, tree planting activity is planned to be held in Shimen, New Taipei City.

Henry Chen, President of Chugai Pharma Taiwan, said that adhering to the patient-centered philosophy, CPT lists oncology, cardiovascular diseases, blood diseases, bone and joint diseases, and autoimmune central nervous system inflammatory diseases as strategic areas, and will communicate with the headquarter to accelerate the introduction of new products into Taiwan market. In the future, CPT is aiming to the top leader in the pharmaceutical industry, to provide outstanding corporate value to meet the needs of patients, family members and medical professionals, and continue to follow a rigorous ethical foundation to engage in businesses that are closely related to human life.

Extracted from the news on Dec.23, 2019 of Economy Daily News.